Literature DB >> 23098852

Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium.

Beamon Agarwal, Matthew J Campen, Meghan M Channell, Sarah J Wherry, Behzad Varamini, James G Davis, Joseph A Baur, James M Smoliga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23098852      PMCID： PMC3646959          DOI： 10.1016/j.ijcard.2012.09.027

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  9 in total

1.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs
Journal:  Circulation       Date:  2010-11-15       Impact factor: 29.690

Review 2.  Therapeutic potential of resveratrol: the in vivo evidence.

Authors:  Joseph A Baur; David A Sinclair
Journal:  Nat Rev Drug Discov       Date:  2006-05-26       Impact factor: 84.694

Review 3.  Resveratrol and health--a comprehensive review of human clinical trials.

Authors:  James M Smoliga; Joseph A Baur; Heather A Hausenblas
Journal:  Mol Nutr Food Res       Date:  2011-06-20       Impact factor: 5.914

4.  Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: evidence from a novel translational in vitro model.

Authors:  Meghan M Channell; Michael L Paffett; Robert B Devlin; Michael C Madden; Matthew J Campen
Journal:  Toxicol Sci       Date:  2012-02-13       Impact factor: 4.849

Review 5.  Cytokines in atherosclerosis: pathogenic and regulatory pathways.

Authors:  Alain Tedgui; Ziad Mallat
Journal:  Physiol Rev       Date:  2006-04       Impact factor: 37.312

6.  One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.

Authors:  João Tomé-Carneiro; Manuel Gonzálvez; Mar Larrosa; María J Yáñez-Gascón; Francisco J García-Almagro; José A Ruiz-Ros; María T García-Conesa; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  Am J Cardiol       Date:  2012-04-19       Impact factor: 2.778

7.  Baseline ICAM-1 and VCAM-1 are increased in initially healthy middle-aged men who develop cardiovascular disease during 6.6 years of follow-up.

Authors:  Caroline Schmidt; Johannes Hulthe; Björn Fagerberg
Journal:  Angiology       Date:  2008-05-25       Impact factor: 3.619

8.  Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study.

Authors:  Gérald Luc; Dominique Arveiler; Alun Evans; Philippe Amouyel; Jean Ferrieres; Jean-Marie Bard; Latifa Elkhalil; Jean-Charles Fruchart; Pierre Ducimetiere
Journal:  Atherosclerosis       Date:  2003-09       Impact factor: 5.162

9.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

Authors:  Silvie Timmers; Ellen Konings; Lena Bilet; Riekelt H Houtkooper; Tineke van de Weijer; Gijs H Goossens; Joris Hoeks; Sophie van der Krieken; Dongryeol Ryu; Sander Kersten; Esther Moonen-Kornips; Matthijs K C Hesselink; Iris Kunz; Vera B Schrauwen-Hinderling; Ellen Blaak; Johan Auwerx; Patrick Schrauwen
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287
  9 in total
  45 in total

Review 1.  Antioxidant effects of resveratrol in the cardiovascular system.

Authors:  Ning Xia; Andreas Daiber; Ulrich Förstermann; Huige Li
Journal:  Br J Pharmacol       Date:  2016-05-06       Impact factor: 8.739

Review 2.  Resveratrol supplementation: Where are we now and where should we go?

Authors:  Marta G Novelle; Devin Wahl; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Ageing Res Rev       Date:  2015-01-24       Impact factor: 10.895

3.  Serum-borne bioactivity caused by pulmonary multiwalled carbon nanotubes induces neuroinflammation via blood-brain barrier impairment.

Authors:  Mario J Aragon; Lauren Topper; Christina R Tyler; Bethany Sanchez; Katherine Zychowski; Tamara Young; Guy Herbert; Pamela Hall; Aaron Erdely; Tracy Eye; Lindsey Bishop; Samantha A Saunders; Pretal P Muldoon; Andrew K Ottens; Matthew J Campen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 4.  The NAD+-Dependent Family of Sirtuins in Cerebral Ischemia and Preconditioning.

Authors:  Nathalie Khoury; Kevin B Koronowski; Juan I Young; Miguel A Perez-Pinzon
Journal:  Antioxid Redox Signal       Date:  2017-08-07       Impact factor: 8.401

5.  Residential proximity to abandoned uranium mines and serum inflammatory potential in chronically exposed Navajo communities.

Authors:  Molly E Harmon; Johnnye Lewis; Curtis Miller; Joseph Hoover; Abdul-Mehdi S Ali; Chris Shuey; Miranda Cajero; Selita Lucas; Katherine Zychowski; Bernadette Pacheco; Esther Erdei; Sandy Ramone; Teddy Nez; Melissa Gonzales; Matthew J Campen
Journal:  J Expo Sci Environ Epidemiol       Date:  2017-01-25       Impact factor: 5.563

Review 6.  Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets.

Authors:  Mandy O J Grootaert; Martin R Bennett
Journal:  Nat Rev Cardiol       Date:  2022-03-30       Impact factor: 49.421

7.  Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells.

Authors:  Katherine E Zychowski; Bethany Sanchez; Rodrigo P Pedrosa; Geraldo Lorenzi-Filho; Luciano F Drager; Vsevolod Y Polotsky; Matthew J Campen
Journal:  Atherosclerosis       Date:  2016-09-22       Impact factor: 5.162

8.  Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers.

Authors:  Christakis Sergides; Marinela Chirilă; Luigi Silvestro; Daphne Pitta; Andreas Pittas
Journal:  Exp Ther Med       Date:  2015-11-25       Impact factor: 2.447

9.  A healthier approach to clinical trials evaluating resveratrol for primary prevention of age‐related diseases in healthy populations.

Authors:  James M Smoliga; E Sage Colombo; Matthew J Campen
Journal:  Aging (Albany NY)       Date:  2013-07       Impact factor: 5.682

10.  Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients.

Authors:  Heidi Cung; Mario J Aragon; Katherine Zychowski; Joe R Anderson; James Nawarskas; Carlos Roldan; Akshay Sood; Clifford Qualls; Matthew J Campen
Journal:  J Transl Med       Date:  2015-03-22       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.